In line with this hypothesis, epacadostat, an inhibitor of IDO1, reduces the release of proinflammatory cytokines by with adverse clinical outcomes and inflammatory properties, including elevated interleukin-1α and β (IL-1α, IL-1β), interleukin-6 (IL-6), interferon-γ (IFN-γ), and tumor necrosis circulating leukocytes from SARS-CoV-2-infected macaques [71]. This evidence concerns the gene IL6 and neoplasm.